


# Q1 Please provide your unique I-PWG Survey Code provided to you by Julian Arbuckle:

Answered: 14 Skipped: 3

#	RESPONSES	DATE
1	1927	5/17/2021 5:16 PM
2	2999	5/17/2021 2:34 PM
3	3444	5/17/2021 8:07 AM
4	2531	5/17/2021 12:32 AM
5	4099	5/14/2021 9:26 PM
6	9901	5/14/2021 6:50 PM
7	2276	5/5/2021 12:52 AM
8	8354	5/4/2021 1:57 PM
9	sorry, didn't see one	4/29/2021 12:11 PM
10	1003	4/27/2021 7:55 PM
11	7507	4/23/2021 5:01 PM
12	6390	4/23/2021 4:29 PM
13	2378	4/22/2021 4:59 PM
14	2772	4/22/2021 1:24 PM

## Q2 How long have you been a member of the I-PWG?


Answered: 17 Skipped: 0



ANSWER CHOICES	RESPONSES
< 1 Year	23.53% 4
1 - 3 Years	23.53% 4
> 3 Years	52.94% 9
TOTAL	17

### Q3 How often to you visit the Members Section of the I-PWG website?


Answered: 17 Skipped: 0



ANSWER CHOICES	RESPONSES	
Frequently (Approximately once a week)	0.00%	0
Often (Approximately 3-4 times a month)	0.00%	0
Rarely (Approximately once a month)	70.59%	12
Never	29.41%	5
<b>TOTAL</b>		<b>17</b>

### Q4 In your role do you provide guidance, advice, and/or support to enable the inclusion of PGx in your company’s clinical trials?

Answered: 17 Skipped: 0



ANSWER CHOICES	RESPONSES	
Yes	94.12%	16
No	5.88%	1
Total Respondents: 17		


## Q5 If you answered “Yes” to Q3 how does your role support your company's PGx strategy? Please describe:

Answered: 16 Skipped: 1

#	RESPONSES	DATE
1	Working toward WGS on all patients in all trials, assisting program teams as they approach the clinic especially for trials with genetic inclusion criteria	5/17/2021 5:16 PM
2	In my role as Genomics Clinical Science Adviser, I support ethical and compliant inclusion of broad scope genomics samples, within clinical studies. These differ to standard PGx in the sense that use is not restricted to disease or drug. My role sits at an interface between clinical study teams (local and global), supporting HBS/biosample groups and the CGR's operational and bioinformatics teams.	5/17/2021 2:34 PM
3	Review ICF language for sample use permission	5/17/2021 1:28 PM
4	standardize wording in Protocol and ICF templates to support any type of PGx work to be done during the clinical trials and after (future exploratory research) as well as facilitate approval of protocol/ICF by ECs/IRBs	5/17/2021 8:07 AM
5	my role is mainly to provide advice and guidance for ADME	5/17/2021 12:32 AM
6	My group reviews the relevant wording in protocol and ICF and also owns the relevant wording in ICF template.	5/14/2021 9:26 PM
7	My role in IPWG helps me to share best practices from the membership back into our strategy for PGX.	5/14/2021 6:50 PM
8	Responsible for biorepository and analysis of omic data and associated biomarker evaluation	5/5/2021 12:52 AM
9	Provide advice on ICF language around sample management and use, including PGx samples	5/4/2021 1:57 PM
10	I think the question meant Q4, I provided support on analysis and reporting PGx in clinical trials so not directly on strategy but help on decision making.	4/29/2021 12:11 PM
11	Review of each ICF version (global, country and site-specific) to ensure PGx language is included and accurate. Participate in IRB/EC negotiations as needed. Track site-specific PGx language against biorepository inventory.	4/27/2021 7:55 PM
12	I'm the current Head of Human Genetics at Eisai, and support the use of human genetics from early discovery through development. In this capacity, I have a strong role to play when it comes to PGx considerations, and in planning for including this criteria in decision-making as it relates to trial design.	4/23/2021 5:01 PM
13	At a high level, I ensure that the language is appropriate in all relevant protocols to allow the collection of PGx samples for (future) use.	4/23/2021 4:29 PM
14	PGx strategy roles up through my group.	4/22/2021 4:59 PM
15	Develop local ICDs-- accommodate local requirements, sites' own templates, answer questions from sites & ECs/IRBs	4/22/2021 1:24 PM
16	I'm leading an effort around PG-PK for clinical trials, and an initiative for genotyping for clinical enlightenment.	4/22/2021 7:01 AM

### Q6 Are you aware that the I-PWG has created PGx-focused education materials for use with clinical trial patients?

Answered: 17 Skipped: 0



ANSWER CHOICES	RESPONSES	
Yes	70.59%	12
No	29.41%	5
TOTAL		17

**Q7 If you answered “Yes” to Q5 have you used any of the materials that are currently available on the I-PWG website and if so which ones? Please describe:**

Answered: 15 Skipped: 2

#	RESPONSES	DATE
1	I have read the Pharmacogenomics Informational Brochure (regional brochure for Japan)	5/17/2021 5:16 PM
2	I haven't used any of the material available	5/17/2021 2:34 PM
3	No	5/17/2021 1:28 PM
4	No I often have issues with accessing the members section of the site	5/17/2021 8:07 AM
5	PGX related to Enzymes and transporters	5/17/2021 12:32 AM
6	I have worked with study management team to make the brochures available to sites at my previous company. At my current company, I have leveraged content of the brochures to develop FAQ to address inquiries from IRBs/ECs.	5/14/2021 9:26 PM
7	Have not had to pull and use them	5/14/2021 6:50 PM
8	No	5/5/2021 12:52 AM
9	None used to date	5/4/2021 1:57 PM
10	na	4/29/2021 12:11 PM
11	No.	4/27/2021 7:55 PM
12	NA	4/23/2021 5:01 PM
13	No.	4/23/2021 4:29 PM
14	Yes, the video and the more recently developed ICD language.	4/22/2021 4:59 PM
15	No	4/22/2021 1:24 PM

## Q8 Are you aware of any of your colleagues using the I-PWG educational materials for use in clinical trials or any other PGx education-related activity? Please describe:


Answered: 15 Skipped: 2

#	RESPONSES	DATE
1	I am unaware	5/17/2021 5:16 PM
2	No	5/17/2021 1:28 PM
3	No, I am not aware	5/17/2021 8:07 AM
4	my colleagues also used materials not from I_PWG, but based on publications	5/17/2021 12:32 AM
5	No. I certainly could have done more to promote the use of these materials...	5/14/2021 9:26 PM
6	No	5/14/2021 6:50 PM
7	No	5/5/2021 12:52 AM
8	No	5/4/2021 1:57 PM
9	not sure	4/29/2021 12:11 PM
10	No.	4/27/2021 7:55 PM
11	I believe one colleague, David Verbel, has communicated this information to stakeholders within the company as it relates to trial design	4/23/2021 5:01 PM
12	No.	4/23/2021 4:29 PM
13	Not yet, have just distributed inside of the company.	4/22/2021 4:59 PM
14	No	4/22/2021 1:24 PM
15	none	4/22/2021 1:18 AM



### Q9 Were you able to navigate the Members Section website with ease to find appropriate materials?


Answered: 16 Skipped: 1



ANSWER CHOICES	RESPONSES	
Yes	75.00%	12
No	25.00%	4
TOTAL		16

### Q10 Would you like to see other materials developed by the I-PWG for use with clinical trial patients or other target audiences?

Answered: 15 Skipped: 2



ANSWER CHOICES	RESPONSES	
Yes	86.67%	13
No	13.33%	2
TOTAL		15

**Q11 If you answered “Yes” to Q9 what materials would you like to see prepared for use with clinical trial patients or other target audiences?  
Please describe:**

Answered: 12 Skipped: 5

#	RESPONSES	DATE
1	Paediatric guidance material, supporting PGx genomics would be interesting	5/17/2021 2:34 PM
2	A FAQ document on terminology, process and IRB/EC response positions. For example details such as name and address of storage location in an ICF. How different companies review and track ICFs permissions. Provide a language library for countries that push back or have regional requirements.	5/17/2021 1:28 PM
3	like PGX for targeted protein, proteins related to efficacy or side effects	5/17/2021 12:32 AM
4	Target audience: IRB/EC Topics: value of exploratory/future/genetic research, data sharing considerations, etc.	5/14/2021 9:26 PM
5	Return of results materials	5/14/2021 6:50 PM
6	Handling of incidental findings, exploratory future research and returning of data and results	5/5/2021 12:52 AM
7	I don't have any specific suggestions at this time	5/4/2021 1:57 PM
8	not sure	4/29/2021 12:11 PM
9	patient-facing materials as well as more sponsor-facing materials.	4/27/2021 7:55 PM
10	Explanations of how generally samples are collected and used, and how results may or may not be returned to participants. How patients can find out more information/resources available to patients that might have an incidental finding related to PGx, etc.	4/23/2021 5:01 PM
11	Additional work in the ICD space may be very useful.	4/22/2021 4:59 PM
12	Have a space just for sharing info and documents. does not need to be very formal.	4/22/2021 7:01 AM

## Q12 If you answered “No” to Q9 why would you not like any other education materials to be developed by the I-PWG? Please describe:

Answered: 6 Skipped: 11

#	RESPONSES	DATE
1	NA	5/14/2021 6:50 PM
2	N/A	5/4/2021 1:57 PM
3	not sure	4/29/2021 12:11 PM
4	NA	4/23/2021 5:01 PM
5	I think what we have is sufficient.	4/23/2021 4:29 PM
6	I don't think they are necessary and also I think they put disproportionate emphasis and real estate on a sample that is piggybacked onto a clinical trial. It is relatively trivial compared to conveying information about the purpose of the trial, the risks of an unapproved drug, no guarantee of benefit, description of what's involved in the study, etc.	4/22/2021 1:24 PM

**Q13 Aside from education materials for use with clinical trial patients do you think that there are other materials that the I-PWG should be developing as part of a broader education effort by the I-PWG? Please describe:**

Answered: 11 Skipped: 6

#	RESPONSES	DATE
1	Template language for consent forms would be useful	5/17/2021 5:16 PM
2	I think the I-PWG should have a stand-alone ICF outline for PGx collection to guide others on the correct placement of information, to avoid redundancy and/or discordance and promote standards across the industry.	5/17/2021 1:28 PM
3	Maybe I-PWG can collaborate with FDA and develop educational materials targeting regulatory agencies so as to reduce the red tape and restrictions on sample export/sample use.	5/14/2021 9:26 PM
4	best practices on doing clinical trials in China in this space	5/14/2021 6:50 PM
5	N/A	5/4/2021 1:57 PM
6	not sure	4/29/2021 12:11 PM
7	Yes, I think there could be benefits in creating materials for commercial development colleagues to understand pros and cons of PGx to development, including potential for cost-savings with trial designs, paired-diagnostics development and opportunities, labeling, etc.	4/23/2021 5:01 PM
8	Perhaps other information on process for sharing of information with subjects/physicians.	4/23/2021 4:29 PM
9	Reinitializing interactions with regulators should be possible in the near future and of use.	4/22/2021 4:59 PM
10	Can't think of any.	4/22/2021 1:24 PM
11	yes. we could develop a Consortium concept or Consortium agreement on which Best Practices and white papers we prefer to apply in our organization. I'm thinking CPIC recommendations. gene specific. Also i-PWG "internal white papers" made with the results of the workstreams.	4/22/2021 7:01 AM


## Q14 What area of the I-PWG website do you visit most often? Please describe:

Answered: 11 Skipped: 6

#	RESPONSES	DATE
1	Member contact, publications	5/17/2021 5:16 PM
2	Publications	5/17/2021 8:07 AM
3	ADME	5/17/2021 12:32 AM
4	Task forces	5/14/2021 9:26 PM
5	I would say the homepage	5/14/2021 6:50 PM
6	Currently, I don't visit the site often	5/4/2021 1:57 PM
7	I just learn about the website in this survey. Will have to try and provide feedback	4/29/2021 12:11 PM
8	Publications section	4/27/2021 7:55 PM
9	I don't visit the site that often, but when I do it is for specific questions often related to consent and regulatory concerns.	4/23/2021 5:01 PM
10	Members section and education materials.	4/22/2021 4:59 PM
11	Have gone to the website rarely, although I can't think of the last time. I recall trying to find the names of IPWG members there.	4/22/2021 1:24 PM

### Q15 Do you currently use the Publication link?


Answered: 16 Skipped: 1



ANSWER CHOICES	RESPONSES	
Yes	25.00%	4
No	75.00%	12
TOTAL		16

## Q16 Would it be useful to add relevant PDFs on the site?

Answered: 14 Skipped: 3




ANSWER CHOICES	RESPONSES	
Yes	92.86%	13
No	7.14%	1
TOTAL		14



### Q17 Would you like to see articles of interest within the field of PGx posted on the I-PWG website?


Answered: 16 Skipped: 1



ANSWER CHOICES	RESPONSES	
Yes	87.50%	14
No	12.50%	2
TOTAL		16

## Q18 Would you be willing to submit articles of interest for posting on the I-PWG website?


Answered: 15 Skipped: 2



ANSWER CHOICES	RESPONSES	
Yes	80.00%	12
No	20.00%	3
TOTAL		15

### Q19 Do you currently use the Membership Contact List to find members?


Answered: 17 Skipped: 0



ANSWER CHOICES	RESPONSES	
Yes	11.76%	2
No	88.24%	15
TOTAL		17

## Q20 Would you be interested in better understanding the global reach of I-PWG?


Answered: 16 Skipped: 1



ANSWER CHOICES	RESPONSES	
Yes	93.75%	15
No	6.25%	1
TOTAL		16

## Q21 Do you currently use the Job Postings link to post or find jobs?

Answered: 17 Skipped: 0



ANSWER CHOICES	RESPONSES	
Yes	17.65%	3
No	82.35%	14
TOTAL		17

## Q22 Do you have any suggestions or recommendations that you feel would improve the website? Please describe:

Answered: 5 Skipped: 12

#	RESPONSES	DATE
1	The link to pharmacogenomics education resources only point to the PGx brochure in Japanese. There should also be the PGx brochure in English, the biomarker brochure, the one-page summary for IRBs/ECs, etc.	5/14/2021 9:26 PM
2	N/A	5/4/2021 1:57 PM
3	I probably missed the info about the website. will like to try out first.	4/29/2021 12:11 PM
4	This is a wonderful organization I've just joined, and discover the good mechanism of functioning.	4/22/2021 7:01 AM
5	none	4/22/2021 1:18 AM